


# Frontiers in Clinical Drug Research

(CNS and Neurological Disorders)



Editor:  
**Zareen Amtul**

**Bentham Books**

**Frontiers in Clinical Drug  
Research - CNS and  
Neurological Disorders**

*(Volume 12)*

Edited by

**Zareen Amtul**

*The University of Windsor  
Department of Chemistry and Biochemistry  
Windsor, ON  
Canada*

# **Frontiers in Clinical Drug Research - CNS and Neurological Disorders**

*(Volume 12)*

Editor: Zareen Amtul

ISSN (Online): 2214-7527

ISSN (Print): 2451-8883

ISBN (Online): 978-981-5179-84-2

ISBN (Print): 978-981-5179-85-9

ISBN (Paperback): 978-981-5179-86-6

©2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>PREFACE</b> .....	i
<b>LIST OF CONTRIBUTORS</b> .....	iii
<b>CHAPTER 1 RECENT DRUGS TESTED IN CLINICAL TRIALS FOR ALZHEIMER'S AND PARKINSON'S DISEASES TREATMENT: CURRENT APPROACHES IN TRACKING NEW DRUGS</b> .....	1
<i>Fernanda Majolo, Lavynia Ferreira Hoffmann, Wilian Luan Pilatti Sant'Ana, Celso Alves, Joana Silva, Alice Martins, Rui Pedrosa, Bruno Dahmer, Guilherme Liberato da Silva, Luís Fernando Saraiva Macedo Timmers and Márcia Inês Goettert</i>	
<b>INTRODUCTION</b> .....	2
<b>ALZHEIMER'S DISEASE</b> .....	4
Etiopathogenesis and Physiopathology .....	4
Diagnosis .....	5
Treatment – Approved Drugs .....	6
Prevention .....	6
Clinical Trials .....	7
<i>Donepezil</i> .....	15
<i>Methylphenidate</i> .....	16
<i>Rivastigmine</i> .....	17
<i>Suvorexant</i> .....	17
<i>Zolpidem</i> .....	18
<i>Zopiclone</i> .....	19
<i>AXS-05</i> .....	20
<i>Umibecestat (CNP520)</i> .....	20
<b>PARKINSON'S DISEASE</b> .....	20
Etiopathogenesis and Physiopathology .....	21
Diagnosis .....	21
Treatment – Approved Drugs .....	22
Prevention .....	23
Clinical Trials .....	23
<i>Inosine</i> .....	24
<i>LY03003</i> .....	25
<i>Pimavanserin</i> .....	25
<i>Droxidopa</i> .....	25
<i>Pramipexole</i> .....	26
<i>Opicapone (BIA 9-1067)</i> .....	27
<i>Safinamide</i> .....	27
<i>DA-9701</i> .....	27
<b>NATURE AS A VALUABLE SOURCE OF CHEMICAL ENTITIES FOR PD AND AD THERAPEUTICS</b> .....	28
<b>FUTURE ADVANCES IN THE FIELD - TRACKING NEW DRUGS</b> .....	41
<b>CONCLUDING REMARKS</b> .....	44
<b>REFERENCES</b> .....	45
<b>CHAPTER 2 NEUROBIOLOGY OF PLACEBO: INTERPRETING ITS EVOLUTIONARY ORIGIN, MEANING, MECHANISMS, MONITORING, AND IMPLICATIONS IN THERAPEUTICS</b> .....	59
<i>Akash Marathakam, Vimal Mathew and MK Unnikrishnan</i>	
<b>INTRODUCTION</b> .....	60
The Context of Health and Disease: The Mind-Body Continuum .....	61

Placebo and the Therapeutic Context: the Evolutionary Backdrop .....	61
Measuring the Placebo Effect .....	66
The Physiology of Placebo: Mechanistic Aspects .....	67
Placebo Effect (PE): A Distraction in Clinical Trials [62] .....	69
Leveraging the Placebo Effect .....	71
<b>CONCLUSION</b> .....	73
<b>REFERENCES</b> .....	74

**CHAPTER 3 ROLE OF GUT MICROBIOTA IN NEUROINFLAMMATION AND NEUROLOGICAL DISORDERS** ..... 80

*Khadga RajNavneet Arora, Rohit, Anupam Awasthi, Mayank Patel, Ankit , Chaudhary, Shamsher Singh and G.D. Gupta*

<b>INTRODUCTION</b> .....	81
<b>COMPOSITION AND STRUCTURE OF THE HUMAN GI MICROBIOTA</b> .....	81
<b>INTERACTION OF GUT AND NERVOUS SYSTEM, GUT-BRAIN-AXIS</b> .....	82
<b>MICROBIAL METABOLITES AND CELLULAR COMPONENTS ON CNS</b> .....	84
<b>MICROBIOTA AND NEURODEVELOPMENT</b> .....	85
<b>MICROBIOTA AND AGEING</b> .....	86
<b>MICROBIOTA AND NEUROINFLAMMATION</b> .....	87
Alzheimer's Disease .....	88
<i>Impact of Gut Microbiota on Brain</i> .....	88
<i>Role of Gut Microbiota in AD</i> .....	89
<i>Probiotics</i> .....	91
Depression .....	92
<i>Clinical Features</i> .....	94
<i>Classification, Prevalence, and Course of Depression</i> .....	94
<i>Risk Factor for Depression</i> .....	95
<i>Genetic Influences</i> .....	95
<i>Biochemical Basis of Depression</i> .....	95
<i>Synaptic Transmission</i> .....	95
<i>Monoamine Hypothesis</i> .....	96
<i>Transporters for Neurotransmitter Reuptake</i> .....	97
<i>Impact of Gut Microbiota in Depression</i> .....	97
<i>Gut Dysbiosis Association with Antidepressant Drugs</i> .....	98
<i>How Gut Microbiota Alters in Depression</i> .....	99
Parkinson's Disease .....	101
<i>Clinical Features of PD</i> .....	101
<i>Pathology/Etiology</i> .....	101
<i>Mechanisms of Neurodegeneration in PD</i> .....	102
<i>Role of Gut Microbiota in PD</i> .....	102
<i>Current Pharmacotherapy to Treat PD</i> .....	106
<i>Microbiota Targeted Strategies to Control PD</i> .....	108
Multiple Sclerosis .....	109
<i>Clinical Features</i> .....	110
<i>Pathology</i> .....	111
<i>Mechanisms of Demyelination and Axonal Dysfunction in MS</i> .....	111
<i>Role of Gut Microbiota in MS</i> .....	112
<i>Diet and Gut Microbiota in Multiple Sclerosis</i> .....	113
<i>The Role of Microbiota in Multiple Sclerosis: Clinical Trials</i> .....	114
<i>Current Pharmacotherapy to Treat MS</i> .....	116
<i>Targeting Gut Microbiome to Treat MS</i> .....	117

Autism Spectrum Disorder .....	118
<i>Pathomechanism of ASD</i> .....	120
<i>The Gut Microbiome's Role in ASD's Underlying Mechanisms</i> .....	121
<i>Role of Gut Microbiota in ASD</i> .....	121
<i>The Therapeutic Perspective of ASD by Targeting Gut Microbiota</i> .....	123
<b>CONCLUSION</b> .....	124
<b>REFERENCES</b> .....	124
<b>CHAPTER 4 THE ROLE OF AGE IN PEDIATRIC TUMORS OF THE CENTRAL NERVOUS SYSTEM</b> .....	138
<i>Nesibe S. Kutahyalioğlu and Dylan V. Scarton</i>	
<b>INTRODUCTION</b> .....	139
Definition of Pediatric Tumors in the CNS .....	141
Overview of the Current State of the Field .....	143
Key Evidence-Based Factors Impacting Patients Outcomes .....	144
<b>CLINICAL ASPECTS</b> .....	144
Diagnosis and Screening .....	146
Treatment Considerations and Management of Side Effects .....	150
Long-Term Outcomes and Quality of Life .....	153
<b>AGE-RELATED TRENDS</b> .....	153
Importance of Understanding the Role of Age in the 0-14 Years Range .....	154
Importance of Understanding the Role of Age for 14-21 Years Range .....	155
<b>MULTIDISCIPLINARY HEALTHCARE TEAMS</b> .....	156
Role of Collaboration .....	157
<i>Roles of Multidisciplinary Care Team During Diagnosis</i> .....	157
<i>Roles of Multidisciplinary Care Team During Treatment</i> .....	158
<i>Roles of Multidisciplinary Care Team After Treatment</i> .....	160
Effective Teamwork and Clinical Management .....	160
Patient-and-Family Centered Care .....	162
<b>CONCLUSION</b> .....	164
Summary of Findings .....	164
Future Directions for Research .....	164
Implications for Clinical Practice and Patient Care .....	165
<b>REFERENCES</b> .....	165
<b>CHAPTER 5 DRUG REPURPOSING IN CNS AND CLINICAL TRIALS: RECENT ACHIEVEMENTS AND PERSPECTIVES FOCUSING ON EPILEPSY AND RELATED COMORBIDITIES</b> .....	171
<i>Gabriela Machado Parreira, Antonio Carlos Pinheiro de Oliveira, Leonardo de Oliveira Guarnieri and Rafael Pinto Vieira</i>	
<b>INTRODUCTION</b> .....	172
The Drug Repurposing Context .....	172
Drug Repurposing Aiming at Cognitive Improvement and Anticonvulsant Activity in Epilepsy .....	173
<i>Memantine</i> .....	177
<i>Methylphenidate</i> .....	178
<i>Natalizumab</i> .....	179
<i>Everolimus</i> .....	180
<i>Melatonin</i> .....	181
<i>Digoxin</i> .....	181
DEPRESSION: INTERFACE WITH EPILEPSIES IN A DRUG REPURPOSING CONTEXT .....	182



<i>Ketamine</i> .....	183
<i>Infliximab</i> .....	187
<i>Minocycline</i> .....	187
<i>Fluoxetine and Escitalopram</i> .....	189
<b>CONCLUSION</b> .....	189
<b>ACKNOWLEDGEMENTS</b> .....	190
<b>REFERENCES</b> .....	190
<b>CHAPTER 6 PROGRESS ON THE DEVELOPMENT OF OXIME DERIVATIVES AS A POTENTIAL ANTIDOTE FOR ORGANOPHOSPHORUS POISONING</b> .....	203
<i>Manjunatha S. Katagi, M.L Sujatha, Girish Bolakatti, B.P. Nandeshwarappa, S.N.     Mamledesai and Jennifer Fernandes</i>	
<b>INTRODUCTION</b> .....	204
History .....	204
<i>Organophosphorus Compounds</i> .....	205
<i>General Structure Of An OP</i> .....	205
<i>Classification of OP Compounds [19 - 23]</i> .....	206
<i>OP Poisoning</i> .....	210
<i>Mechanism of Toxicity</i> .....	210
<i>Pharmacokinetics Of Organophosphorus Compounds [42–44]</i> .....	211
<i>Clinical Features of Organophosphorus Poisoning</i> .....	212
<i>Management and Treatment [19, 20, 46]</i> .....	213
<i>Muscarinic Antagonist Drug</i> .....	214
<i>Oxime As Acetylcholinesterase Reactivator</i> .....	215
<i>Structure Activity Relationships</i> .....	216
<i>Other Therapies</i> .....	218
<i>Others</i> .....	219
<i>Design And Synthesis Of New AChE Reactivators</i> .....	220
<b>DISCUSSION</b> .....	243
<b>CONCLUSION AND OUTLOOK</b> .....	245
<b>ACKNOWLEDGEMENTS</b> .....	245
<b>REFERENCES</b> .....	246
<b>SUBJECT INDEX</b> .....	256

## PREFACE

Brain disorders are a major public health and economic concern. The causes of these disorders are heterogeneous, and so are the treatment options. State-of-the-art advances in scientific techniques, evolving clinical observations, and diagnostic accuracies to study the neurobiology of different diseases are very illuminating, and assist in not only deciphering the physiology of brain disorders but also the mechanisms that make people more vulnerable to these disorders.

As our understanding is evolving, our knowledge is expanding, and so is our book series *Frontiers in Clinical Drug Research - CNS and Neurological Disorders*. The organization and content of volume 12 of our book series like its predecessors sets the physiology of the brain by outlining the pathology of neurodegenerative disorders, the role of neuroinflammation in neurological disorders, aging in brain tumors, comorbidities in epilepsy as well as placebo effect based on available empirical evidence by actively formulating, synthesizing, and analyzing these pieces of evidence. The relationships between these medical illnesses are complex, multifactorial, and bidirectional.

Since the aim of the series is to include current advancements in the field, rather covering the materials exhaustively, this volume also precisely educates readers about the salient examples of the latest advancement happening in the translational research of various brain ailments, encompassing neurodegenerative disorders and neurological disorders. The volume also contextualizes the engaging and accessible introduction to drug repurposing for neurological disorders. The last chapter of the volume also discusses the organophosphorus poisoning or intoxication emergency, a very scarcely discussed topic, with reference to neuroactive drugs that can be used to treat it.

Briefly, **Chapter 1** highlights the current approaches used for tracking the new drugs by reviewing recent drugs tested in clinical trials for the treatment of Alzheimer's and Parkinson's diseases. **Chapter 2** summarizes an intellectual and conceptual framework for understanding the neurobiology of placebo by interpreting its evolutionary origin, meanings, mechanisms, monitoring, and implications from therapeutics' perspective. **Chapter 3** discusses the role of gut microbiota in neuroinflammation and neurological disorders. **Chapter 4** glances the role of age in pediatric tumors of the central nervous system. **Chapter 5** comprehensively and critically assesses the current knowledge about epilepsy when it is comorbid with the full range of medical disorders with reference to drug repurposing in clinical trials. **Chapter 6** reviews the progress on the development of oxime derivatives as a potential antidote for organophosphorus poisoning.

Therefore, each chapter in the book very ostensibly introduces beginners in the basic science to the primary as well as advanced knowledge in the field. At the same time, these chapters are equally valuable not just for other mental health professionals, and psychiatrists but also for a wide range of medical specialists as well. Besides, it offers researchers, postdoctoral fellows, and students in diverse fields of neurobiology, neurology and neuroscience the tools they need to obtain a fundamental background in the major neurodegenerative, and neurological disorders. In conclusion, the volume provides a glimpse into the future that we are moving toward by exploring a greater understanding of the common pathways that mediate neuropathological illnesses, symptoms, and the relevant pathophysiological and neurophysiological phenomenon.

*ii*

The timely assistance provided by the editorial staff; Mr. Mahmood Alam (Director Publications), and Ms. Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers is highly appreciated.

**Zareen Amtul**  
The University of Windsor  
Department of Chemistry and Biochemistry  
Windsor, ON  
Canada

## List of Contributors

<b>Ankit Chaudhary</b>	Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Anupam Awasthi</b>	Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Antonio Carlos Pinheiro de Oliveira</b>	Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil
<b>Akash Marathakam</b>	Department of Pharmaceutical Chemistry, National College of Pharmacy Kozhikode, Kerala 673602, India
<b>Alice Martins</b>	MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche, Portugal
<b>Bruno Dahmer</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil
<b>B.P. Nandeshwarappa</b>	Department of Studies in Chemistry, Davangere University, Shivagangothri, Tholhunase - 577 007, Karnataka, India
<b>Celso Alves</b>	MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche, Portugal
<b>Dylan V. Scarton</b>	George Mason University, Interdisciplinary Program in Neuroscience, Fairfax, Virginia, USA
<b>Fernanda Majolo</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil
<b>Guilherme Liberato da Silva</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil
<b>G.D. Gupta</b>	Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Girish Bolakatti</b>	Department of Pharmaceutical Chemistry, GM Institute of Pharmaceutical Sciences and Research, Davangere - 577 006, Karnataka, India
<b>Gabriela Machado Parreira</b>	Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil
<b>Joana Silva</b>	MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche, Portugal
<b>Jennifer Fernandes</b>	Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences, Mangalore-574 160, Karnataka, India
<b>Khadga Raj</b>	Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Leonardo de Oliveira Guarnieri</b>	Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil
<b>Lavynia Ferreira Hoffmann</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil

<b>Luís Fernando Saraiva Macedo Timmers</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado, Brazil
<b>Mayank Patel</b>	Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>M.L Sujatha</b>	Department of Studies in Chemistry, Davangere University, Shivangothri, Tholhunase - 577 007, Karnataka, India
<b>Márcia Inês Goettert</b>	Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado, Brazil
<b>Manjunatha S. Katagi</b>	Department of Pharmaceutical Chemistry, Bapuji Pharmacy College, Davangere - 577 004, Karnataka, India
<b>MK Unnikrishnan</b>	Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, 575018 Mangaluru, Karnataka, India
<b>Nesibe S. Kutahyalioğlu</b>	Karabuk University, Faculty of Health Science, Karabuk, Turkey
<b>Navneet Arora</b>	Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Rui Pedrosa</b>	MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche, Portugal
<b>Rafael Pinto Vieira</b>	Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil
<b>Rohit</b>	Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>Shamsher Singh</b>	Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India
<b>S.N. Mamledesai</b>	Department of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi-Ponda - 403 401, Goa, India
<b>Vimal Mathew</b>	Department of Pharmaceutics, National College of Pharmacy Kozhikode, Kerala 673602, India
<b>Wilian Luan Pilatti Sant'Ana</b>	Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado, Brazil

---

**CHAPTER 1**

---

**Recent Drugs Tested in Clinical Trials for Alzheimer's and Parkinson's Diseases Treatment: Current Approaches in Tracking New Drugs**

**Fernanda Majolo<sup>1</sup>, Lavynia Ferreira Hoffmann<sup>1</sup>, Wilian Luan Pilatti Sant'Ana<sup>2</sup>, Celso Alves<sup>3</sup>, Joana Silva<sup>3</sup>, Alice Martins<sup>3</sup>, Rui Pedrosa<sup>3</sup>, Bruno Dahmer<sup>1</sup>, Guilherme Liberato da Silva<sup>1</sup>, Luís Fernando Saraiva Macedo Timmers<sup>1,2</sup> and Márcia Inês Goettert<sup>1,2,\*</sup>**

<sup>1</sup> Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil

<sup>2</sup> Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado, Brazil

<sup>3</sup> MARE, Marine and Environmental Sciences Centre, ESTM, Polytechnic of Leiria, Peniche, Portugal

**Abstract:** Affecting more than 50 million people worldwide and with high global costs annually, neurological disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are a growing challenge all over the world. Globally, only in 2018, AD costs reached an astonishing \$ 1 trillion and, since the annual costs of AD are rapidly increasing, the projections estimate that these numbers will double by 2030. Considering the industrial perspective, the costs related to the development of new drugs are extremely high when compared to the expected financial return. One of the aggravating factors is the exorbitant values for the synthesis of chemical compounds, hindering the process of searching for new drug candidates. In the last 10-year period, an average of 20 to 40 new drugs were approved per year, representing a success rate of less than 6%. However, the number of referrals for new drug orders and/or applications remained at approximately 700 each year, reinforcing the difficulty in the process of identifying and developing novel drugs. Regarding neurodegenerative diseases, the FDA (USA) approved 53 new therapies in 2019, including 48 new molecules and, from these, three are medicines and two are vaccines. The main drugs recommended for the treatment of these disorders are included in the following classes: Dopamine supplement (Levodopa), Monoamine oxidase (MAO) inhibitor (Selegiline, Rasagiline), Dopamine agonist (Apomorphine, Pramipexole), and Acetylcholinesterase inhibitor (Donepezil, Rivastigmine, Galantamine). Additionally, the current pharmacological treatments are not able to cure these patients and considering the etiological complexity and the prevalence of neurological disorders, scientists have a

---

\* **Corresponding author Márcia Inês Goettert:** Graduate Program in Biotechnology, University of Vale do Taquari (Univates), Lajeado, Brazil and Graduate Program in Medical Sciences, University of Vale do Taquari (Univates), Lajeado, Brazil; E-mails: marciagoettert@gmail.com and m.goettert@uni-tuebingen.de

Zareen Amtul (Ed.)

All rights reserved-© 2024 Bentham Science Publishers

great challenge in exploring new therapies and new molecules to find an adequate and viable treatment for these diseases. Clinical trials are essential in this process and thus, this chapter describes the most important drugs that were targets of phase III and IV clinical studies in the last five years, associated with the most common neurological disorders worldwide, AD and PD. Information about mechanisms of action, experimental studies in other diseases that support their use, and chemical structure of the drugs are included in this chapter. Additionally, nature as a source of valuable chemical entities for PD and AD therapeutics was also revised, as well as future advances in the field regarding tracking new drugs to get successful results and critical opinions in the research and clinical investigation.

**Keywords:** Acetylcholinesterase inhibitor, Clinical trials, FDA, Neurological disorders.

## INTRODUCTION

Neurological diseases (ND) are a heavy burden carried by patients, their families, communities, and governments [1]. As the world population grows old, especially in developed nations, the combined annual costs of ND are rapidly rising [2]. In the United States, the social burden of ND is up to \$ 800 billion, and disorders like Parkinson's disease (PD), Alzheimer's disease (AD), and other dementias represent more than one-third of these ND [2]. For elderly, ND can dramatically increase health care costs due to other associated comorbidities, such as Idiopathic Parkinson's Syndrome (IPS) disease and fall-related fractures [3]. It is estimated that about 61% of the IPS patients will have at least one fall during the course of the disease, and 39% will suffer multiple falls, generating high disease-specific costs [3]. In 2015, German data showed that IPS patients' treatment cost was more than € 3.2 billion, which amounted to about 1% of Germany's total annual medical expenses [3]. Projections estimate that by 2050 only AD dementia will have a devastating impact, affecting 131 million people worldwide [4]. In 2018, AD costs were nearly \$ 1 trillion and, since the annual costs of AD are rapidly increasing, the projections estimate that these numbers will double by 2030 [4].

To reduce this social burden related to ND as a whole, not only for AD and PD, a global effort towards discovering new drug therapies that may reduce these costs is welcome. That is a concern mainly because many ND still have poorly defined or even undefined etiopathogenesis [5]. In addition, many ND present subjective and context-dependent clinical manifestations, making the sample selection for treatment trials, using clinical criteria, inevitably heterogeneous [5]. Due to this heterogeneity, the inclusion criteria for the studies are often more rigorous, adding to the time, cost, and risk to the drug development process [6]. All these aspects, when combined, reflect the success rates of new drugs for ND, which are the lowest for any therapeutic area [6]. For example, in the early 2010 decade, less

than 10% of the potential drugs that started clinical testing reached the market, and from the compounds that eventually moved on to phase III testing, less than 50% got approval [6]. This scenario explains why clinical research programs for ND tend to be longer and more complex than those for other diseases [6].

In 2008, Pharmaceutical Research and Manufacturers of America (PhRMA) presented a report that contained more than five hundred drugs for neurological disorders, which were still in the development stage [6]. When analyzed in detail, the reports data demonstrated that the research and development (R&D) pipeline contained previously known drugs, undergoing repurposing processes, *i.e.*, tested for new indications [6].

Regarding the pipeline of drugs and biologics in clinical trials for the treatment of AD, a recent study that has utilized a survey of annual pipeline reports of the past five years provided a longitudinal insight into clinical trials and drug development for AD [4]. According to the Common Alzheimer's and Related Dementias Research Ontology (CADRO) for classifying treatment targets and mechanisms of action, the results revealed that, in 2020, there were 121 agents in clinical trials to treat AD [4]. Among them, there were 29 agents in phase 3, 65 in phase 2, and 27 in phase I trials. Also, the data showed testing of twelve agents in trials targeting cognitive enhancement, twelve intended to treat neuropsychiatric and behavioral symptoms, and 97 agents in disease modification trials [4]. For example, compared to the 2019 pipeline, these data showed a growth in the number of disease-modifying agents targeting pathways other than the amyloid or the tau pathways [4]. Finally, the clinical trials' data from the last five years showed a progressive emphasis on non-amyloid targets. Those candidate treatments aim at targets involving mechanisms like inflammation, synapse, neuronal protection, vascular factors, neurogenesis, and interventions on epigenetics [4]. Also, data revealed significant growth in the repurposed agents' pipeline as well [4].

In recent years, several drugs with the potential to modify the disease and with neuroprotective effects are being evaluated in preclinical and clinical studies. The United States stands out for conducting the largest number of phase III and phase IV clinical studies, both for AD and PD Fig (1). Thus, this chapter summarizes the most important drugs that were targets of clinical studies from 2015 to 2020, associated with the most common neurological disorders worldwide: AD and PD. The approached clinical studies are related to phase III and IV studies registered on *clinicaltrials.gov*. Data like mechanisms of action, experimental studies in other diseases that support their use, and chemical structure of the drugs are included in this chapter. Also, a revision focused on nature as a source of valuable chemical entities for PD and AD therapeutics is also reported. Finally, future adv-



**CHAPTER 2****Neurobiology of Placebo: Interpreting its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics****Akash Marathakam<sup>1</sup>, Vimal Mathew<sup>2</sup> and MK Unnikrishnan<sup>3,\*</sup>**<sup>1</sup> Department of Pharmaceutical Chemistry, National College of Pharmacy Kozhikode, Kerala 673602, India<sup>2</sup> Department of Pharmaceutics, National College of Pharmacy Kozhikode, Kerala 673602, India<sup>3</sup> Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, 575018 Mangaluru, Karnataka, India

**Abstract:** Placebo is defined as the therapeutic response to inert treatment. However, this is a bit simplistic because comprehending the biological basis of the placebo effect requires understanding the entire therapeutic context and the patient immersed in it. Placebo does not cure the disease but alleviates symptoms. The placebo impact must be seen in the context of the recipients' cultural milieu, psychosocial background, the tone and tenor of the accompanying verbal communication (caring, indifferent, unfriendly), therapeutic rituals (*e.g.*, tablet, injection, or a procedure, including diagnostic tests), symbols (white coat, syringe, the diagnostic paraphernalia), and its meanings to the patient (past experiences and personal hope). Placebo is the inert treatment juxtaposed against the broad context of the accompanying sensory and sociocultural inputs that signal benefit. It could also be the harm in the case of nocebo. A major objective of a standard clinical trial is to eliminate or at least minimise the influence of placebo. Many methods have been devised to measure and eliminate placebo responders in the trial populations. The neurological basis of the placebo effect is complex and must have an evolutionary basis because the susceptibility to placebos may be traced back to animals and birds. The placebo effect probably owes its evolutionary origin to signalling sickness and the ability to draw comfort from winning sympathetic attention and care from conspecifics. Pain being a complex sensory experience with a strong affective component, the neuronal pathways that reflect both sensory experience and the affective components have been explored in the study of the placebo effect. Placebo research, having expanded from psychology to neurology, presently involves research tools that include pharmacology, brain imaging, genetics, animal models, *etc.* This review will discuss multiple dimensions of the placebo effect, including evolutionary, cultural, psychosocial, and neurological aspects, in addition to providing cues for transformational implications in clinical trials and therapeutic modalities that benefit

\* **Corresponding author MK Unnikrishnan:** Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, 575018 Mangaluru, Karnataka, India; Tel: +918089007260; E-mail:unnikrishnan.mk@nitte.edu.in

**Zareen Amtul (Ed.)****All rights reserved-© 2024 Bentham Science Publishers**

society. Contemporary medicine is demonising placebo because it is a confounder in clinical trials. It would be much more useful if the healthcare system can harness the therapeutic potential of the placebo effect by manipulating the therapeutic context.

**Keywords:** Cognition, Evolutionary biology, Neurobiology, Placebo.

## INTRODUCTION

The urge to heal is intrinsic to all forms of life. The enduring recuperative drive, the *sine qua non* for survival, is mostly unconscious and innate, and begins at the molecular level -- even the DNA is equipped with the technology for self-repair. The most primitive parts of the brain handle the most fundamental life-sustaining functions, demonstrating its evolutionary antiquity as well as the minimal need for 'intelligent' interventions by the conscious mind. The healing power of physicians, until recently, rested mostly on the results of the placebo effect [1]. This is self-evident today because we know that many of the pre-World War remedies were either useless or positively harmful. There is a scandalous account of how Calvin Coolidge Jr died, quite possibly from the treatment he received for infection [2]. Despite so many ineffective and hazardous remedies, the medical profession has consistently enjoyed society's awe and trust for thousands of years. Voltaire probably had the placebo effect in mind when he famously said, "The art of medicine consists of amusing the patient while nature cures the disease" [3].

There is a growing tendency to attribute the combined role of mind and body in fighting and recovering from illnesses [4]. Studies suggest that subjective perceptual states such as mindsets and expectations influence human physiology. For instance, young adults could improve their vision when exposed to a mindset patterned to suit pilots and athletes. For instance, vision improved when subjects learned to read the Snellen Eye Charts in reversed progression [5]. Those who were scared of catching the flu in winter actually expressed more real flu symptoms. This is consistent with the idea that the brain influences metabolic and endocrine regulation based on environmental challenges, appropriate to the context of available resources. Such a scheme has an evolutionary advantage because expectations prepare the body to cope better with an anticipated event.

The many case records of miraculous cures reinforce the value of subjective interventions. For instance, at the famous healing shrine of Lourdes, literature reports 176 cases of cancer that regressed without treatment [6]. Considering that people of different religious faiths experienced such cures, success appears to have depended more on the patient's state of mind than religious faith. On the other hand, these cures do not violate the laws of nature. They merely hasten the

normal reparative process [7]. ‘No one has grown a new limb or an eye at Lourdes’, quotes a review on placebo!

### **The Context of Health and Disease: The Mind-Body Continuum**

A recent study by Harvard University threw up a surprise [8]. When diabetics were asked to drink the same sweetened beverage from different bottles, with labels declaring different sugar contents, the rise in blood sugar in each individual was proportionate to the labelled sugar content, not the actual sugar content in what was consumed. In another study by the same department, they employed manipulated ‘fast’ and ‘slow’ clocks to modify the perception of time in type 2 diabetics. Interestingly, a fall in blood sugar correlated with the perceived time interval, not the actual time interval. In other words, the metrics of the environment must be meaningful to the mind; subjective perception can control the metabolic trajectory.

The role of the mind in metabolic regulation is not limited to diabetic subjects [9]. Women who were conditioned to consider work as a kind of exercise achieved greater weight control and a fall in BMI (body mass index). In another study, the ghrelin levels in subjects consuming milkshakes depended on the labelled calorific value rather than the true calorific value [10]. Yet another study showed that just believing to follow a low-calorie diet (while actually on an energy-balanced diet) can help reduce body mass. Endocrine regulation, as well as its potential disruption, is influenced by the conscious mind [11].

There is an evolutionary advantage in such perceptual neuroendocrine controls. Consciously anticipated events can potentially prepare the body to become future-ready. Maintaining the time course of blood sugar must have been much more difficult in the food-insecure primitive environment. In corollary, an evolutionary mismatch can explain the recent surge in metabolic disorders.

### **Placebo and the Therapeutic Context: the Evolutionary Backdrop**

While the placebo effect is the response to inert treatment, the placebo phenomenon, in its totality, is a lot more complex [12]. PE constitutes a number of diverse variables/ entities that create the therapeutic context as a whole. The words uttered by the physician during encounters at the hospital, the body language of physicians, nurses and bystanders, the therapeutic rituals of diagnosis and treatment, the seemingly trivial, but ominous symbols and signals, such as white coats, stethoscopes, the smells of antiseptics, signboards notifying say, ‘Cancer Hospital’, (possibly a ‘death sentence’), *etc.*, combine to create the therapeutic context. Every accompanying sensory/social stimulus that signal benefit, along with all the procedural rituals of therapeutic interventions, merges

## Role of Gut Microbiota in Neuroinflammation and Neurological Disorders

**Khadga Raj<sup>1\*</sup>, Navneet Arora<sup>2</sup>, Rohit<sup>2</sup>, Anupam Awasthi<sup>1</sup>, Mayank Patel<sup>1</sup>, Ankit Chaudhary<sup>1</sup>, Shamsher Singh<sup>1</sup> and G.D. Gupta<sup>3</sup>**

<sup>1</sup> Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India

<sup>2</sup> Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab-142001, India

<sup>3</sup> Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab-142001, India

**Abstract:** The prevalence of neurological diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Multiple sclerosis (MS) are growing in the world, but their pathogenesis is unclear and effective treatment does not exist. Neuroinflammation is associated with many neurodegenerative mechanisms involved in neurodegenerative diseases. The human gut microbiota is an aggregate of microorganisms that live in the gastrointestinal tract (GIT) that plays a crucial role in maintaining human health and the pathogenesis disease condition. The microbiota can affect neuronal function through neurotransmitters, vitamins, and neuroactive microbial metabolites like short-chain fatty acids. The change in gut microbiota architecture causes increased permeability of the intestine and immune system activation, contributing to systemic inflammation, neurological injury, and eventually neurodegeneration. Available data suggest that the microbiota send signals to the central nervous system (CNS) by activating afferent neurons of the vagus nerve *via* neuroendocrine and neuroimmune pathways. The molecular interaction between the gut/microbiome and CNS is complex and bidirectional, ensuring gut homeostasis and proper digestion. Evidence suggests that dysfunction of the gut-brain axis could be a significant factor leading to many disorders of CNS. In this chapter, we explore how the gut microbiome may affect brain function and the development of neurological disorders. In addition, we are also trying to highlight the recent advances in improving neurological disease by supplemental probiotics and faecal microbiota transplantation *via* the concept of the gut-brain axis to combat brain-related dysfunction.

**Keywords:** Alzheimer's disease, Central nervous system, Parkinson's disease, Gastrointestinal tract, Microbiota, Multiple sclerosis, Neuroinflammation.

\* **Corresponding author Khadga Raj:** Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India; Tel: +91-8288979902; E-mail: bishalarann@gmail.com

## **INTRODUCTION**

The human microbiome comprises bacteria, viruses, archaea and eukaryotic organisms that live in and on our bodies. These microbes potentially affect human physiology, both in health and illness conditions [1]. The human microbiota is estimated to include  $10^{13}$ – $10^{14}$  microbial cells, with a microbial cell-to-human cell ratio of about 1:1. The varied gut microbiota comprises bacteria classified as Firmicutes, Bacteroidetes, and Actinobacteria [2]. This diverse and complex microbiome functions as a functional extension of host genomes, with an estimated 50–100-fold increase in gene count compared to the host. These additional genes have resulted in various enzymatic proteins that were not previously encoded by the host and serve a vital function in aiding host metabolism and therefore contribute to the control of host physiology [3]. The microbiota helps the host in many ways, including improving gut integrity and shaping the intestinal epithelium, harvesting energy, protecting against pathogens, and regulating host immunity. However, these processes may be disturbed due to changed microbial composition, a condition known as dysbiosis. However, these processes may be concerned due to altered microbial composition, a condition known as dysbiosis. With the development of more sophisticated techniques for profiling and characterizing complex ecosystems, it has become increasingly clear that the microbiota plays a role in a wide variety of intestinal and extra-intestinal illnesses [4].

## **COMPOSITION AND STRUCTURE OF THE HUMAN GI MICROBIOTA**

The human gastrointestinal tract is a complicated system that starts at the oesophagus and ends at the anus, with most data collected to date from the distal colonic microbiota owing to specimen collecting practicalities. Significant physiological factors like as pH, bile content, and transit time change throughout the GI tract, contributing to the existence of different microbial populations in the upper and lower GI tracts [5]. The gut microbiota is not as varied as bacteria found in other body parts and has a high degree of functional redundancy. A comprehensive inventory of the human gut microbiome's functional capability was recently acquired, with 9879896 genes discovered using a combination of 249 newly sequenced and 1018 previously published samples. The study identified country-specific microbial signatures, suggesting that environmental factors, such as diet, shape gut microbiota composition, and possibly also by host genetics [6]. However, it is noted that microbiotas with varying designs may exhibit some functional redundancy, resulting in comparable protein or metabolite profiles. This knowledge is crucial for developing treatment therapeutic strategies to modify and shape the microbial community in disease. It is critical to evaluate

cognition, hearing, vision, and speech first to interpret examination results accurately.

### **INTERACTION OF GUT AND NERVOUS SYSTEM, GUT-BRAIN-AXIS**

The gut-brain connection was identified for the first time by Gershon American physicist at the end of the 19<sup>th</sup> century. The gut-brain axis communicates in two directions between the brain and the gut. For instance, the CNS influences gut function in reaction to psychological and physical stresses, altering motility, secretion, and immunological reactivity, while alterations in the gut microbiota may result in behavioral and neurochemical changes [7]. The microbiota-gut-brain axis control the GI tract and CNS through the vagus nerve, hypothalamic–pituitary–adrenal axis, and various cytokines.

The vagus nerve has been a primary focus in recent studies of the gut-brain axis because it represents a major bidirectional connection between the body and the brain. The vagus nerve is the 10th cranial nerve and serves several GI organs such as the oesophagus, stomach, small intestine, and colon, as well as other digestive organs such as the liver, pancreas, and gallbladder, as well as cardiopulmonary organs such as the heart, lung, trachea, and aortic arch [8]. Sensory (afferent) and motor (efferent) fibres coexist in the vagus nerve, but their cell bodies are located in different places: sensory neurons in the nodose/jugular ganglia adjacent to the jugular foramen and motor neurons in the dorsal motor nucleus of the vagus (DMV) and the nucleus ambiguus in the brainstem. Sensory neurons of the vagus nerve are genetically diverse, with a wide range of molecular machines for sensing stretch, tension, and other chemical signals, as well as connecting with other sensory cells such enteroendocrine cells, neuroepithelia bodies, taste buds, and enteric neurons. The vagus nerve's genetically unique sensory neurons are expected to encode different body information [8].

The gut microbiota controls the gut-brain axis, where brain communication to the GI tract is linked to permeability, motility, secretion, and immunological modulation in the brain's function. The gut-brain axis comprises the immune system, neuroendocrine system, GIT, ENS, ANS, and CNS, controlling afferent and efferent regulation. The GI tract regulates endocrine and exocrine secretions, motility, and microcirculation and is also involved in immunological and inflammatory processes. Numerous brain regions, including the hypothalamus, pituitary adrenal (HPA), and vagus nerve system, regulate metabolic, immunological, and homeostatic functions [9].

Changing the composition of the gut microbiota may disrupt gut homeostasis and affect the CNS and many metabolic diseases such as inflammatory bowel disease (IBD). The health-promoting bacteria concentration is reduced when the

## The Role of Age in Pediatric Tumors of the Central Nervous System

Nesibe S. Kutahyalioğlu<sup>1,\*</sup> and Dylan V. Scarton<sup>2</sup>

<sup>1</sup> Karabuk University, Faculty of Health Science, Karabuk, Turkey

<sup>2</sup> George Mason University, Interdisciplinary Program in Neuroscience, Fairfax, Virginia, USA

**Abstract:** Pediatric tumors of the central nervous system (CNS) are the second most common type of solid childhood cancer. As such, they have a major effect on the rates of morbidity and mortality in children. CNS tumors originate from abnormal cells in the brain and/or spinal cord, which can be classified as either benign or malignant. They can be further subdivided into different categories based on several principal aspects, such as tumor location, histopathology, and developmental age. Among these various characteristics, age is one of the most consequential determinants for CNS tumors. Specific groups between 0 and 21 years of age, for instance, have radically divergent landscapes in terms of their tumor incidence and unique biology. Depending on the age of the child, key case features may differ like the clinical evaluation, medical diagnosis and prognosis, recommended therapy and treatment courses, anticipated responses and tolerability to treatment, and management of side effects. Effective teamwork is another crucial component for the successful management of pediatric CNS tumors. In patient-and-family-centered care, ensuring a detailed education of the children and their families, as well as their involvement in the decision-making process where appropriate, is imperative. To determine the best available options for the patient, multidisciplinary medical teams will often deliberate over all of the possible procedures. The holistic care provided by these inter-professional collaborations for this vulnerable population will depend on the age of the child, in addition to the level of patient and family participation. Evidence shows that support and counseling of the patient and their family during the entire treatment process can have a significant impact on outcomes. This chapter will review the essential diagnostic and prognostic considerations of childhood CNS tumors, with special emphasis placed on favorable therapies and treatments, including in-depth discussions around the multi-faceted responses to treatment and the management of its side effects. In particular, this content will highlight the critical role that age, and interdisciplinary healthcare teams play in comprehensive disease management.

---

\* Corresponding author Nesibe S. Kutahyalioğlu: Karabuk University, Faculty of Health Science, Karabuk, Turkey; E-mail: nesibekutahyalioğlu@karabuk.edu.tr

**Keywords:** Age, Brain, Central Nervous System, CNS, Disease Management, Multidisciplinary, Pediatric, Quality of Life, Spinal Cord, Tumors, Team, Treatment.

## INTRODUCTION

2020 was a harrowing year in human health history. For Andrew Kaczynski and Rachel Louise Ensign, it was no different. Six months after then-President Donald Trump declared a state of emergency over COVID-19 in the United States (U.S.), Andrew and Rachel received news that no parent would wish upon another—their six-month-old daughter, Francesca “Beans” Kaczynski, had just been diagnosed with a rare and aggressive brain cancer known as atypical teratoid rhabdoid tumor (ATRT). This type of tumor often manifests in the cerebellum or brain stem, which are largely responsible for coordinating movement and controlling basic body functions, respectively. Symptoms include headaches, nausea, and vomiting, as well as balance loss and an abnormally large head size in infants. Prior to Beans’ supervising physician developing a novel treatment protocol at the Dana-Farber Cancer Institute in Boston, Massachusetts, ATRT was effectively a death sentence for kids. Now, the survival rate for children with ATRT over the age of three can be as high as 70%; however, if the child is under one, then their chance of survival plummets to less than 10%. How can merely two years of life account for more than a seven-fold difference in surviving such a pernicious disease? This tragic discrepancy is due in part to treatment protocols not recommending radiation therapy for babies before they reach 12 months. With limited options in the wake of this grim prognosis, Beans passed away just three months later on Christmas Eve [1].

Although this case is fortunately far and few between, pediatric tumors of the central nervous system (CNS) continue to affect families around the nation and across the world every day. While an average of only 60 cases of ATRT are identified in the U.S. each year [2], 500 more children are diagnosed with medulloblastoma [3]. Approximately one in every four American children with a brain tumor has medulloblastoma, making it the most common type among adolescence [4]. Overall, depending on the country, the annual incidence of pediatric brain tumors ranges from 1.15 to 5.14 cases per 100,000 children [5]. These sobering rates translate to tens of thousands of children developing CNS tumors worldwide, wherein the causes are mostly unknown a number do not survive. The survivors encounter immense challenges related to their physical and psychological health, in addition to various social and intellectual obstacles. Nevertheless, children with brain tumors generally have a better prognosis than adults with similar conditions [6]. For all forms of brain tumors, approximately 3 out of 4 children survive for at least 5 years after their diagnosis [7]. Clinical



outcomes for these vulnerable patients have improved tremendously in recent decades, with the implementation of advanced screening measures and the development of targeted treatment strategies [8]. The field of pediatric oncology continues to grow and progress in what is a very active area of research.

This chapter will explore the essential diagnostic and prognostic considerations of childhood CNS tumors, with special emphasis placed on favorable therapies and treatments, including in-depth discussions around the multi-faceted responses to treatment and the management of its side effects. In particular, this content will highlight the critical role that age and multidisciplinary healthcare teams play in comprehensive disease management. The key learning objectives are to:

1. Discuss the procedures for performing a clinical evaluation and rendering medical diagnoses/prognoses of CNS tumors, according to the fundamental features of the case.
2. Examine the suggested, evidence-based treatment and therapy options for CNS tumors in children, depending on the medical diagnosis and prognosis.
3. Investigate the patient response to treatment and management of side effects, given relevant circumstances like developmental age and tumor presentation.
4. Review the importance of enhancing holistic care approaches among multidisciplinary healthcare teams by improving the quality of care for vulnerable pediatric populations affected by childhood CNS tumors.

The ultimate goal of this chapter is to provide a comprehensive summary on how CNS tumors are managed in children of different ages while also emphasizing the role of multidisciplinary team care, from diagnosis to post-treatment. Clinically relevant descriptions are given for the most common tumor types in addition to their overall epidemiology, pathological presentation, clinical diagnosis, and treatment regimens. Tumor classifications are separated by their severity scale, from low- to high-grade, with some genetic data included as well. Although the diagnostic criteria and treatment modalities may be similar for these two broad groups of tumors, their management and outcomes are quite different. Furthermore, despite a degree of standardization in treatment strategies among many practitioners and institutions, a variety of emerging and experimental techniques are also employed on a case-by-case basis. General management principles are described in the context of standard therapy, but other approaches may be considered equally valid. This complete presentation should better inform the reader to the different management options for pediatric CNS tumors.

## CHAPTER 5

## Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities

Gabriela Machado Parreira<sup>1</sup>, Antonio Carlos Pinheiro de Oliveira<sup>2</sup>, Leonardo de Oliveira Guarnieri<sup>3,\*,#</sup> and Rafael Pinto Vieira<sup>1,\*,#</sup>

<sup>1</sup> Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil

<sup>2</sup> Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil

<sup>3</sup> Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil

**Abstract:** Central Nervous System (CNS) disorders are a massive burden on the global health system, including a broad range of clinical conditions, such as epilepsies, depression, dementia, multiple sclerosis, and Parkinson's disease. Permanent efforts are being made to find early, non-invasive, and effective diagnostic methods, as well as efficient and safe drug-based treatments for CNS conditions. Nevertheless, many patients displaying these clinical conditions still face the lack of an effective pharmacotherapy to cure the diseases or at least to properly control the progression of symptoms. Currently, epilepsies present an estimated prevalence of 0.5%–1% worldwide, and around 30% of the patients remain refractory to the available drug treatment. The comorbidities that affect epileptic patients, such as cognitive impairment and depression, are major public health challenges. This scenario highlights the urgent need for approving new therapeutic tools for CNS diseases. A successful development process of a new compound presenting therapeutic potential can range up to 20 years and cost hundreds of millions of US dollars, from the initial characterization of the *in vitro* chemical and biological properties until clinical trials. Additionally, drug development has a low success rate in the case of CNS conditions. In this context, drug repurposing (or drug repositioning, DR) is an alternative way to reduce the cost and accelerate the process of a drug-based treatment approach since it identifies a novel clinical application for an existing compound already approved for a distinct indication. In the present chapter, we aim to describe recent outcomes of DR

---

\* Corresponding authors Rafael Pinto Vieira and Leonardo de Oliveira Guarnieri: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais and Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil; E-mails: leoguarnieri@gmail.com, vieirarp@icb.ufmg.br

# These authors equally contributed to this work.

Zareen Amtul (Ed.)

All rights reserved-© 2024 Bentham Science Publishers

aiming at CNS pathological conditions, especially discussing the recent clinical trials and their impacts on future endeavors in the search for the management of epilepsies and related comorbidities.

**Keywords:** Central Nervous System, Clinical Trial, CNS Diseases, Cognitive Impairment, Drug Repurposing, Drug Repositioning, Epilepsy, Depression, Pharmacotherapy.

## INTRODUCTION

### The Drug Repurposing Context

Historically, conventional approaches in relation to investing cost and time in a drug discovery campaign would normally involve millions of dollars and decades as average requirements to achieve the target outcomes and introduce final products into the market. This scenario has not substantially changed in recent years, and apparently, it has no expectations to be far from this pattern in the future. Even considering computational campaigns and further modern strategies to improve the time spent in the first *in silico*, *in vitro* and other preclinical steps, the time required to assure the efficacy and safety of new pharmaceutical entities by clinical studies is mandatory. Furthermore, recent estimation of these data reinforces that the average cost required to bring a new approved compound to clinical use is extremely high, being almost 1 billion dollars. In the specific case of drugs targeting the Central Nervous System (CNS), the mean estimates range from around 500 million to more than 1,8 billion dollars of expenditures. Simultaneously, the percentage of final successful compounds in this high-cost context is considerably low, with clinical trial success rates ranging from only 15% to around 51% [1].

The above-mentioned items that contribute to this scenario are acceptably referred to as top facts that pave the way to the continuing search for less expensive alternatives targeting approved drugs, side-by-side with the urgent pharmacotherapy needs in public health systems. In this context, drug repurposing (or drug repositioning, DR) emerges as one of the most promising pathways.

The main idea of DR is focused on using already approved drugs for new therapeutic applications. The history of DR is relatively recent in therapy, and one of the most representative cases is thalidomide [2]. The drug, which was synthesized in the early 1950s by the company Ciba in Switzerland, has been extensively used for years as an antiemetic agent for pregnant women worldwide [3]. However, the first reports on thalidomide-related congenital malformations were raised in the 1960s [4, 5], and the use of the drug was systematically banned.

Simultaneously, researchers have started investigations on alternative applications for the compound, culminating in surprising and successful applications on lepra skin eruptions [6 - 9] and multiple myeloma, also including thalidomide derivatives in this last case [10 - 13]. Besides thalidomide, other drugs have experienced DR pathways, including the recent and successful administration of systemic dexamethasone in the treatment of patients with COVID-19 [14, 15].

In this chapter, we intend to discuss promising approaches, especially clinical ones, targeting new applications of already approved drugs in the context of CNS disorders. The new applications described here are centered on solving drug-resistant epilepsy and two of its most relevant comorbidities, cognitive impairment and depression.

### **Drug Repurposing Aiming at Cognitive Improvement and Anticonvulsant Activity in Epilepsy**

Epilepsies are chronic conditions mainly characterized by the presence of recurrent seizures. The manifestation of these pathological conditions might occur in different forms, including tonic-clonic convulsions. In terms of biochemical and pathophysiological alterations, epilepsies display modifications in the electrical function of the brain tissue, which might be caused by an imbalance between inhibition and excitation events, resulting in abnormal and excessive neuronal activity [16].

Epileptic seizures present different causes. This etiology scenario ranges from genetic to non-heritable pathological alterations, which might be acquired from other medical conditions. All these possible causes might lead to different types of seizures [17]. In general, the diagnosis pathway of an epileptic patient in clinical practice follows two stages. In this process, the focus of the first stage is based on classifying the seizure type or syndrome, followed by the second stage, which is characterized by the search for the disease's cause. Classifications of epilepsies have been extensively dedicated to the characterization of the first stage. However, the cause of the pathological condition is considered of paramount importance in defining the proper pharmacotherapy, as well as the management of the clinical condition during the patient's life [16].

According to recent data, around 70 million people in the world are diagnosed as epileptic patients, and these numbers suggest a current incidence rate of 61.4 in 100,000 people [18, 19]. Antiepileptic drugs (AEDs) are the first choice in the pharmacotherapy of epilepsies, and approximately 70% of patients properly respond to the treatment by using a monotherapy, while about 20-30% of total patients require polytherapy. Despite the current availability of drugs, about one-

## CHAPTER 6

## Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning

Manjunatha S. Katagi<sup>1,\*</sup>, M.L. Sujatha<sup>2</sup>, Girish Bolakatti<sup>3</sup>, B.P. Nandeshwarappa<sup>2</sup>, S.N. Mamledesai<sup>4</sup> and Jennifer Fernandes<sup>5</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry, Bapuji Pharmacy College, Davangere - 577 004, Karnataka, India

<sup>2</sup> Department of Studies in Chemistry, Davangere University, Shivagangothri, Tholhunase - 577 007, Karnataka, India

<sup>3</sup> Department of Pharmaceutical Chemistry, GM Institute of Pharmaceutical Sciences and Research, Davangere - 577 006, Karnataka, India

<sup>4</sup> Department of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi-Ponda - 403 401, Goa, India

<sup>5</sup> Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences, Mangalore-574 160, Karnataka, India

**Abstract:** Nowadays, organophosphorus poisoning is the most common emergency throughout the world. Two functionally different types of drugs are used in common to treat such intoxication cases. The first type includes the reactivators of acetylcholinesterase (AChE)-oximes, which have the capability to restore the physiological function of inhibited AChE. The second type includes anticholinergic, such as atropine that antagonizes the effects of excessive ACh by blocking muscarinic receptors. Alternatively, anticholinergic and reactivators may be co-administered to get synergistic effects. At muscarinic and nicotinic synapses, organophosphorus compounds inhibit AChE release by phosphoryl group deposition at the enzyme's active site very quickly. AChE regenerative process can be accelerated by detaching the OP compound at -OH group of the enzyme. OP compound combines with the AChE enzyme forming a complex and making it inactive. After ageing of the inactive state of AChE, it is difficult to break the complex to regenerate the enzyme resulting in acetylcholine accumulation at synapses. To counter the effect of OP compound, oximes catalyse the reactivation of active AChE by exerting nucleophilic attack on the phosphoryl group. Oximes theoretically remove OP compound from the complex by acting on phosphoryl bond resulting in enzyme reactivation. Reactivation of AChE inhibited by OP compounds through the above mentioned approach poses certain limitations. There is no universal antidote capable of effectively restoring AChE inhibi-

\* Corresponding author **Manjunatha S. Katagi:** Department of Pharmaceutical Chemistry, Bapuji Pharmacy College, Davangere-577 004, Karnataka, India; Tels: +91 8192 221459, +91 9886499160; E-mail: manju\_mpharm@rediffmail.com

ted by wide-ranging OP compounds. The oxime reactivators are efficient only when administered before the “ageing” of AChE-OP complex. Anticholinergic drugs, like atropine, are effective only on muscarinic receptors but not on nicotinic receptors (nAChRs).

**Keywords:** Acetylcholine, Acetylcholinesterase, Atropine, Obidoxime, Butyrylcholinesterase, HI-6, Organophosphorus, Poisoning: Oxime, Reactivation, 2-PAM.

## INTRODUCTION

### History

The history of organophosphate (OP) compounds began in 1800, when Moschnine [1, 2] synthesized a mono ester named tetraethyl pyrophosphate (TEPP). The process was first published in 1854 by de Clermont [3]. Nearly 80 years later in 1934, Dr. Gerhard Schrader, a German chemist, synthesized hundreds of OPs including parathion and tabun (dimethyl phosphoroamidocyanidate), sarin (isopropyl methylphosphonofluoridate), and soman (O-Pinacolylmethylphosphonofluoridate). Schrader later also synthesized a series of fluorine-containing esters including diisopropylfluorophosphate (DFP) and sarin, pyrophosphate esters including TEPP and octamethylpyrophosphortetramide (OMPA), and thio and thiono phosphorus esters including parathion and its oxygen analog paraxon [4, 5] led by observations of Lange and Kruger, who described the synthesis of two OP compounds and noted that their vapour inhalation produced certain health effects, engaged in the exploration of this type of compounds. Their work resulted in the synthesis of parathion; one of the most frequently used OP pesticide in recent decades. After II World War, thousand of OP compounds were synthesized worldwide for various purposes (pesticides, nerve agents in medicine and in chemical warfare, flame retardants and parasiticides in veterinary medicine). Due to the lack of persistence in the environment and in exposed individuals and due to lesser insect resistance development in comparison to organochlorine pesticides, the OP pesticides are today the most commonly used group of pesticides throughout the world. It should be emphasized, that from several points of view (public health and intensive agriculture), their use today is a must and not an option. Although their persistence in environment is relatively low, the extensive use of OP pesticides in modern agriculture has raised several problems regarding environmental and food safety issues [6 - 8].

The OP compounds have a wide variety of applications, hence is a serious threat for occupational hazard, self-poisoning, unintentional misuse, terrorist attack and

threats of warfare use, not only for army rather civilian targets as well. Organophosphates are mainly used for civilian purposes as a pesticides or acaricides, *etc.* but their acute toxicity is comparable to the organophosphonates, developed for military purposes.

OP poisoning has been a frequent cause of admission of people to hospitals and Intensive Care Units (ICU) in developing countries [9]. OP poisoning causes about 3 million acute intoxications annually, 0.3 million of which lead to fatalities [10]. OPs that were developed as chemical warfare nerve agents (CWAs) are all highly toxic and dangerous [11 - 13]. OP nerve agents have been used and are most likely to be used in the future by terrorists and dictators around the world because of their relatively easy synthesis and availability of suitable delivery systems [14]. Warfare and terrorist use of CWAs include the Aum Shinrikyo terrorist attack in the Tokyo subway in 1995, the 1980–1988 Iraq–Iran war where Iraq reportedly used nerve agents against Iranian troops and later on Kurd civilians and the murder of a family member of the North Korea Leader, Kim Jong Nam on February 2017 in Kuala Lumpur [15 - 17]. Despite international efforts aimed at regulating and lessening the use of these environmentally toxic compounds, more than 100 different OP compounds are still being used intensively as pesticides, with only unreliable or sporadic monitoring of the environment and workers involved in their use.

### ***Organophosphorus Compounds***

Organophosphorus compounds are esters, amides or thiol derivatives of phosphoric, phosphonic, phosphinic acids, and phosphorothioic or phosphonothioic acids. The phosphonic acid derivatives are more toxic than the phosphoric acids (Inchem.org) whose oxygen atom can be substituted by sulphur or nitrogen atoms [18]. In other words, it is an organic compound that contains phosphorus as an integral part of the molecule and formed by the reaction of alcohol and phosphoric/phosphonic/phosphinic acids.

### ***General Structure Of An OP***

The basic structure of an OP compound consists of the following;

- a. A central phosphorus atom (P).
- b. P is double bonded to either oxygen or sulphur.
- c. A leaving group which is specific to the individual organophosphorus. It is a labile acyl residue (halide, cyano, phenol, or thio group).
- d. R<sub>1</sub> and R<sub>2</sub> groups which are ethyl or methyl, alkyl, alkoxy, alkylthio or amino group.

## SUBJECT INDEX

### A

Abnormalities 90, 93, 102, 110, 117, 122  
 neuronal 90  
 neuropsychiatric 102  
 spinal fluid 110  
 stress response 93  
 thyroid 117  
 Acetylcholine 15, 16, 38, 39, 43, 86, 89, 90,  
 205, 207, 208, 209, 212  
 acetylhydrolase 208  
 neurotransmitter 43, 212  
 Acetylcholinesterase 1, 2, 14, 179, 204, 205,  
 208, 221, 222, 229, 232, 238, 240, 243  
 drug 179  
 inhibited 238, 240, 243  
 inhibitor 1, 2  
 AChE catalytic activity 210  
 Acid(s) 29, 30, 69, 84, 107, 206, 218, 236  
 arachidonic 69  
 asiatic 30  
 boswellic 29  
 ferulic 107  
 glutamic 236  
 hydroxamic 218  
 nicotinic 84  
 phosphinic 206  
 phosphonothioic 206  
 Activities 16, 35, 36, 39, 45, 99, 113, 119  
 cholinergic 16  
 enzymatic 45  
 glutathione peroxidase 35  
 immunological 113, 119  
 inhibitory 36  
 microglial 99  
 proteasomes 39  
 Adrenocorticotrophic hormone 116  
 Agents 28, 189, 216  
 anti-inflammatory 189  
 chemotherapeutic 216  
 neuroprotective 28  
 Alzheimer's 1, 2, 4, 5, 11, 36, 81, 89, 178

dementia 5  
 disease 1, 2, 4, 11, 36, 81, 89, 178  
 Amyloid precursor protein (APP) 4, 20, 36  
 Anti-inflammatories, non-steroidal 6  
 Anti-inflammatory cytokines 117  
 Anticholinesterase 214  
 Antidepressants drugs 100  
 Antiepileptic pharmacotherapy 175, 181  
 Antigen-presenting cells (APCs) 112, 147  
 Antinociceptive mechanism 68  
 Apoptosis 28, 29, 36, 38, 39, 40, 41, 89  
 inhibition 39, 41  
 mitochondria-dependent 40  
 Astrocytes 112, 182  
 activating 112  
 Astrocytomas, pilocytic 143, 150, 155

### B

Bacteria-derived endotoxins 123  
 Bacterial 99, 108  
 commensals 99  
 migration 108  
 Brain 86, 88, 96, 99, 146, 152  
 cancers 146, 152  
 diseases 86, 88  
 -imaging techniques 96  
 maturation 86  
 stress 99  
 Brain tumors 16, 140, 142, 143, 144, 146,  
 150, 155, 156, 157, 159, 160  
 malignant 142

### C

*Campylobacter jejuni* 90  
 Cancer 42, 61, 74, 84, 117, 144, 145, 148,  
 153, 157  
 chemotherapy 74  
 malignancies-thyroid 117  
 Cancerogenicity 245

Zareen Amtul (Ed.)

All rights reserved-© 2024 Bentham Science Publishers



## *Subject Index*

Chemotherapy 74, 152, 153, 156, 158, 159, 160  
  adjvant 153  
  -induced vomiting 74  
CNS tumors 139, 141, 142, 144, 145, 146, 153, 154, 155, 156, 157, 158, 164, 165, 166  
Cognitive 5, 6, 8, 16, 17, 37, 40, 41, 42, 85, 90, 102, 105, 172, 173, 174, 175, 179, 180  
  functions 8, 16, 17, 40, 41, 42, 85, 90, 179  
  impairment 5, 6, 37, 102, 105, 172, 173, 174, 175, 179, 180  
Components 89, 107  
  neuroactive 107  
  targeting neuroinflammatory 89  
Computerized tomography 148  
Conditions 94, 98, 99, 161, 174, 188  
  inflammatory 188  
  medical 174  
  neurocognitive 161  
  psychopathological 94  
  stressful 98, 99

## **D**

Deep brain stimulation (DBS) 23  
Deficits 30, 41, 93, 120, 152, 157, 180  
  cellular resilience 93  
  mitochondrial 41  
  neurological 157  
  nutritional 120  
Degenerative brain processes 122  
Delirium, postoperative 17  
Dementia 2, 4, 5, 6, 15, 18, 20, 23, 102, 103, 172  
  vascular 15  
Demyelination 88, 109, 110, 111, 112  
  neuronal 111  
Depression 93, 94, 95, 96, 97, 98, 99, 100, 172, 183, 184, 185, 186, 187, 188, 189  
  epilepsy-related 184, 188, 189  
  nonendogenous 96  
  targeting 189  
Destruction, neuronal 88  
Diabetes mellitus 21  
Diet 6, 62, 65, 82, 88, 113, 115  
  and gut microbiota in multiple sclerosis 113  
  balanced 115

## *FCDR - CNS and Neurological Disorders, Vol. 12 257*

  changed 115  
  energy-balanced 62  
  restricted 88  
Diffusion 149  
  restricted 149  
Diseases 2, 19, 26, 81, 83, 84, 88, 89, 90, 94, 98, 100, 107, 117, 118, 149, 154, 160, 189  
  cardiovascular 84, 160  
  cerebrovascular 154  
  chronic obstructive pulmonary 19  
  hepatobiliary 26  
  inflammatory bowel 83, 98, 118  
  intestinal 107  
  mental 94, 100  
  metabolic 83, 90  
  metastatic 149  
  neurological 2, 81, 88  
  progressive neurological 89  
  -thyroiditis 117  
  transmitted 189  
Disorders 1, 2, 5, 18, 19, 20, 21, 25, 27, 46, 62, 70, 81, 85, 86, 87, 88, 91, 93, 94, 102, 112, 119, 120, 121, 124, 161, 172, 175, 180, 183, 190  
  Alzheimer's disease 87  
  autism spectrum 88, 119, 120, 175  
  autistic 121  
  autoimmune 88  
  eye 25  
  inflammatory 112, 121  
  intestinal 91  
  life-threatening 94  
  major psychiatric 5  
  mental 93  
  metabolic 62  
  mood 86, 102, 161  
  neurodegenerative 20, 21  
  neurodevelopmental 124  
  neurologic 18  
  neuropsychiatric 102, 190  
  panic 70  
  stress-induced 27  
Dizziness 25, 26, 175  
Dopamine 22, 103  
  metabolism 22, 103  
  neuron degeneration 103  
  neurotransmission 22  
Dopaminergic neuron degeneration 24

Drugs 3, 6, 7, 11, 15, 17, 18, 22, 23, 25, 27, 42, 45, 100, 116, 173, 174, 175, 177, 178, 179, 181, 187, 190, 205  
 anti-epileptic 190  
 anticholinergic 205  
 antidepressant's 100  
 antiepileptic 174, 177, 178, 179, 181  
 immunomodulatory 116  
 Dysbiosis, intestinal 84, 118  
 Dysfunction 4, 17, 21, 27, 81, 84, 86, 92, 94, 105  
 age-related biological 21  
 brain-related 81  
 cognitive 17, 92  
 intestinal 105  
 metabolic 84  
 neurodegenerative 4  
 telomere 21  
 Dyskinesia 114  
 Dysplastic gangliocytoma 147

**E**

Enzyme 16, 22, 38, 44, 45, 97, 124, 204, 209, 210, 212, 216, 218, 221, 223, 224, 227, 228  
 antioxidant 38  
 catalytic activity 216  
 cholinesterase 16  
 digestive 124  
 metabolic 97

**F**

Factors 37, 41, 105, 107, 123  
 macrophage migration inhibitory 123  
 neuroactive 107  
 platelet-derived growth 123  
 pro-inflammatory 41  
 tumour necrosis 37, 105  
 Faecal microbiota transplantation (FMT) 45, 63, 71, 81, 115, 118, 123, 124, 186  
 Fatty acid-binding proteins (FABPs) 45  
 Fibromyalgia 71  
 Flu symptoms 63  
 Fractional anisotropy (FA) 186  
 Function 81, 83, 84, 88, 102, 105  
 facial muscle 102  
 homeostatic 83  
 immunological 84, 105

neurological 88  
 neuronal 81  
 Functional dyspepsia (FD) 27

**G**

Gastrointestinal 25, 26, 90, 94, 106, 109, 113, 119, 219  
 abnormalities 94  
 decontamination technique 219  
 dysfunction 106  
 homeostasis 113, 119  
 problems 25, 26, 90  
 system 109  
 Genes 39, 82, 99, 103, 121, 146, 177  
 expression 39  
 inherited 99  
 Genetic(s) 20, 60, 67, 119, 120, 121, 145  
 brain imaging 67  
 homogeneity 121  
 mutation 121  
 GI illnesses 123  
 Glioblastoma multiforme 142, 143, 149, 150  
 Glucocerebrosides 33  
 Glutathione 35, 38  
 peroxidase 38  
 reductase 35  
 GM 103, 108  
 dysbiosis 103  
 dysfunction 108  
 Gut 81, 83, 84, 86, 87, 99, 100, 105, 107, 108, 117, 118, 123, 124, 125  
 flora 105  
 homeostasis 81, 83  
 hormones 107  
 microbiome 81, 86, 87, 99, 100, 108, 117, 118, 123, 124, 125  
 microorganisms 84, 87  
 Gut microbiota 82, 87, 89, 100, 118, 124  
 abnormal 118  
 composition 82, 87, 89, 100  
 dysbiosis 124

**H**

Hallucinations, visual 160  
 Hippocampal neurogenesis 86  
 Homeostasis 43, 90, 121  
 metal ion 121  
 mitochondrial 43

## **Subject Index**

Hormones, postmenopausal 21  
Huntington's disease (HD) 178  
Hypothalamus, pituitary adrenal (HPA) 83

## **I**

Idiopathic Parkinson's syndrome (IPS) 2  
Illnesses 113, 120, 122  
  neurodegenerative 113  
  neurological 120, 122  
Inflammation 31, 84, 88, 92, 94, 95, 99, 105,  
  106, 107, 108, 109, 110, 112, 113, 117,  
  118, 123  
  chronic 88, 118  
  endothelial 31  
  -induced depressed symptoms 95  
  intestinal 105  
  mucosal 106  
  pathological 107  
  reducing 88  
  systemic gastrointestinal 113  
Inflammatory bowel disease (IBD) 83, 85, 98,  
  118, 124  
Information, sensory 100  
Inhibition of mitochondrial apoptosis pathway  
  41  
Injury 6, 15, 18, 21, 38, 81, 88  
  cognitive 38  
  neurological 81  
  traumatic brain 6, 15, 18, 88  
  traumatic head 21  
Insomnia dysarthria 214  
Intestinal 84, 88, 111, 113  
  bacterial flora 113  
  microbiota 84, 88, 111, 113

## **J**

JNK signaling pathway activation 39

## **M**

Magnetic resonance spectroscopy 149  
Major depressive disorder (MDD) 19, 70, 94,  
  95, 98, 100, 186  
Mechanisms 81, 107  
  endocrine 107  
  immunological 107  
  neurodegenerative 81

## **FCDR - CNS and Neurological Disorders, Vol. 12 259**

Medications 9, 18, 19, 45, 46, 63, 90, 94, 103,  
  187  
  anti-inflammatory 90  
  antidepressant 94, 187  
Memory 15, 89, 178  
  dysfunction 15  
  loss 89, 178  
Metabolites, immunomodulatory 118  
Microbial 85, 87, 99, 109  
  composition 87  
  lipopolysaccharides 99  
  metabolites 85, 109  
Microbiome-brain communications 125  
Microbiota 81, 82, 84, 86, 87, 88, 100, 104,  
  112, 113, 114, 118, 123, 124  
  commensal 114  
  composition 88, 118  
  transfer therapy (MTT) 124  
Microorganisms, anti-inflammatory 115  
Migration inhibitory factor (MIF) 123  
Mild cognitive impairment (MCI) 5, 6  
Mitochondrial 28, 29, 32, 33, 34, 35, 36, 41,  
  43, 89, 111  
  apoptosis pathway 41  
  dysfunction 28, 29, 32, 34, 41, 43, 89  
  membrane potential (MMPs) 33, 35, 36,  
  111  
Mitogen-activated protein kinase (MAPKs)  
  33, 41  
Monoclonal antibody 177, 184  
Multiple sclerosis (MS) 81, 109, 110, 111,  
  112, 113, 114, 115, 119, 122, 178, 180,  
  181  
Mycobacterium tuberculosis 91  
Mycoplasma 112, 188

## **N**

Neoplasms 143  
Neurodegeneration 44, 45, 81, 89, 90, 91, 103,  
  106, 108, 109  
  ongoing 90  
Neurodegenerative diseases 1, 42, 43, 81, 85,  
  88, 178, 189  
  dementia-related 178  
Neuroendocrine 81, 83, 85, 98  
  network 85  
  system 83, 85  
Neuroepithelial tissue 155  
Neuroimaging techniques 71

Neurological 2, 3, 27, 81, 88, 111, 118  
 diseases (ND) 2, 3, 27, 81, 88  
 dysfunctions 111  
 problems 118  
 Neuromuscular junctions 212, 220, 236  
 Neuronal systems 104  
 Neuroprotective 3, 28, 32, 33, 34, 37, 38  
 activity 37  
 effect 3, 28, 32, 33, 34, 38  
 Neurosurgeons, pediatric 152, 153, 159  
 Neurotoxicity, oligomer-induced 38  
 Nuclear magnetic resonance (NMR) 89, 223

## O

Orthostatic hypotension 23, 105  
 Osteoarthritis 71  
 chronic knee 71  
 Oxytocin 71

## P

Parkinsonism 20, 22  
 Parkinson's disease (PD) 1, 2, 3, 10, 15, 20,  
 21, 22, 24, 27, 42, 45, 46, 69, 102, 103,  
 104, 106, 107, 109  
 Pathways 60, 69, 81, 88, 97, 98, 99, 100, 101,  
 103, 112, 125, 180  
 endocrine 125  
 immunological 100  
 inflammatory 99  
 nerve-derived molecular 88  
 neuroimmune 81, 98  
 neuronal 60  
 pro-inflammatory 112  
 Peptides 4, 28, 42, 100, 101, 102, 111, 123  
 autoantigenic 111  
 microbiota gut 102  
 Pesticides, toxic 220  
 Platelet-derived growth factor (PDGF) 123  
 Postural orthostatic tachycardia syndrome (POTS)  
 25  
 Probiotic(s) 107, 124  
 treatment 107  
 therapy 124  
 Processes, metabolic 89  
 Properties 116, 244  
 immunomodulatory 116  
 lipophilic 244

Protein(s) 4, 20, 28, 33, 38, 39, 41, 45, 82, 97,  
 111, 121, 182, 209, 210, 221  
 amyloid precursor 4, 20  
 anti-apoptotic 39  
 chromodomain helicase DNA binding 121  
 fatty acid-binding 45  
 glucose-regulated 38  
 guanine nucleotide-binding 97  
 misfolding 28  
 signaling 182  
 Proteostasis 43

## R

Reactive 32, 38, 39, 41, 91  
 nitrogen species (RNS) 39  
 oxygen species (ROS) 32, 38, 41, 91  
 Refractory status epilepticus (RSE) 187

## S

Schizophrenia 86, 187  
 Selective serotonin reuptake inhibitors  
 (SSRIs) 25, 183  
 Sensory neurons 83, 85, 101  
 Signaling pathway 30, 35, 38  
 Sleep disorders 7  
 Spinal cord 145, 147, 148, 156  
 malignancies 156  
 tumors 145, 147, 148  
 Stress, immunological 101  
 Synaptophysin 33, 37, 40, 41, 42  
 Syndrome 95, 113, 121, 146, 174, 215  
 cancer predisposition 146  
 cholinergic 215  
 depressive 95  
 neurovegetative 95  
 Systemic lupus erythematosus (SLE) 112

## T

Therapies, immunomodulatory 43  
 Timothy syndrome 121  
 Transmission 14, 97, 98, 115, 117  
 chemical 97  
 cholinergic 14, 115  
 intestinal 98  
 monoaminergic 98  
 neuronal 98  
 Treg dysfunction 112

*Subject Index*

*FCDR - CNS and Neurological Disorders, Vol. 12 261*

Tumors 140, 141, 142, 144, 145, 148, 149,  
150, 151, 152, 154, 155, 157, 158, 160,  
164  
germ cell 144, 157  
posterior fossa 144  
Tumour necrosis factor (TNF) 37, 105

**U**

Urinary dysfunctions 23

## ZAREEN AMTUL

---

Prof. Amtul due to her background in clinical psychiatry and neurodegenerative disorders, brings expertise in neuroanatomy, pathophysiology, drug development, and diagnosis of brain disorders. Prof. Amtul's main area of research has been chemical biology and medicinal bioinorganic chemistry. Prof. Amtul has extensively researched the biochemical, molecular, and behavioural substrates of memory impairment in Alzheimer's disease, vascular cognitive impairment, stroke, depression, epilepsy, and frontotemporal dementia-related disorders using biochemistry, structural biology, optogenetics, decoy, and Trojan horse technologies, bioinformatics, and computational biology. She is a recipient of several national and international awards in basic and SoTL research including the J. William Fulbright award from the USA, the Alexander von Humboldt-Stiftung award from Germany, the Ontario Mental Health Foundation, and the CIHR Strategic Training awards from Canada, as well as a few international traveling grants. She is also the recipient of the Pasha Begum Best Mentor Award from the American Society of Science, Engineering, and Technology (ASSET), USA.